Nephrocare Health Services Limited has released its investor presentation for the quarter and half-year ended September 30, 2026. The presentation details the company’s financial performance, including revenue growth and adjusted EBITDA, alongside operational metrics such as the number of guests and treatments. Key highlights include a 23.6% YoY increase in revenue to ₹585.2 crore and a 15.3% YoY increase in Adjusted EBITDA to ₹134.4 crore for H1FY27.
Nephrocare Health Services Presents Q2 and H1FY27 Results
Nephrocare Health Services Limited, through its investor presentation dated November 3, 2026, has disclosed its Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. This disclosure aligns with Regulation 30 of the SEBI Listing Regulations.
Key Financial Highlights (H1FY27 vs H1FY26)
- Revenue from Operations: Increased by 23.6% year-on-year to ₹585.2 Crore.
- Adjusted EBITDA: Rose by 15.3% year-on-year to ₹134.4 Crore. The Adjusted EBITDA margin stood healthy at 23.0%.
- Adjusted Profit After Tax (PAT): Grew by 34.7% year-on-year to ₹76.1 Crore. The Adjusted PAT margin improved to 13.0%.
Key Operational Metrics (H1FY27 vs H1FY26)
- Guests: Increased by 9.6% year-on-year to 38,814.
- Treatments: Increased by 12.6% year-on-year to 21,01,189.
- Revenue Per Treatment (RPT): Increased by 9.7% year-on-year to ₹2,785.
Operational Expansion
The company continues to expand its global footprint. In H1 FY27, Nephrocare Health Services added 40 clinics in India and 11 in the Philippines. Furthermore, the company has entered two new countries: Saudi Arabia and Kazakhstan. The management noted that international business now accounts for 47% of the revenue.
Consolidated Performance Details
For Q2FY27, Revenue from Operations was ₹303.4 Cr., with Adjusted EBITDA at ₹68.9 Cr. and Adjusted EBITDA Margin at 22.7%. The Adjusted Profit After Tax for Q2FY27 stood at ₹39.3 Cr., marking a 28.7% increase over the previous year.
Strategic Outlook
The company emphasizes its strategy to consolidate India leadership, scale operations in the Philippines, Uzbekistan, and Saudi Arabia, and further expand into new markets. Investments in innovation-led digital healthcare and leveraging scale to drive profitability remain key pillars of their growth strategy.
Source: BSE
